* DURECT Corp reported a quarterly adjusted loss of 25 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -47 cents. The mean expectation of three analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -24 cents to -20 cents per share.
* Revenue fell 11.1% to $1.83 million from a year ago; analysts expected $2.73 million.
* DURECT Corp's reported EPS for the quarter was a loss of 25 cents.
* The company reported a quarterly loss of $7.64 million.
* DURECT Corp shares had fallen by 12.4% this quarter and gained 79.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 22.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for DURECT Corp is $6.75 This summary was machine generated from LSEG data May 13 at 09:21 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.22 -0.25 Missed
Dec. 31 2023 -0.33 -0.10 Beat
Sep. 30 2023 -0.42 -0.14 Beat
Jun. 30 2023 -0.51 -0.42 Beat
Comments